These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 11694402

  • 1. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Liso V, Molica S, Capalbo S, Pogliani E, Battista C, Broccia G, Montillo M, Cuneo A, Leoni P, Specchia G, Castoldi G.
    Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
    [Abstract] [Full Text] [Related]

  • 2. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B, Brugiatelli M, Krc I, Losonczi H, Holowiecki J, Planinc-Peraica A, Kusec R, Morabito F, Iacopino P, Lutz D.
    Cancer; 1997 Jun 01; 79(11):2107-14. PubMed ID: 9179056
    [Abstract] [Full Text] [Related]

  • 3. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct 01; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
    Marotta G, Bigazzi C, Lenoci M, Tozzi M, Bocchia M, Lauria F.
    Haematologica; 2000 Dec 01; 85(12):1268-70. PubMed ID: 11114133
    [Abstract] [Full Text] [Related]

  • 6. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 7. CHOP regimen versus intermittent chlorambucil-prednisone in stage B chronic lymphocytic leukemia. Short term results from a randomized clinical trial. French Cooperative Group on Chronic Lymphocytic Leukemia.
    Nouv Rev Fr Hematol (1978); 1988 May 01; 30(5-6):449-52. PubMed ID: 2906118
    [Abstract] [Full Text] [Related]

  • 8. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
    Morabito F, Stelitano C, Callea I, Filangeri M, Oliva B, Sculli G, Callea V, Nobile F, Brugiatelli M.
    Haematologica; 1996 May 01; 81(3):224-31. PubMed ID: 8767527
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
    Sun XF, Su YS, Liu DG, Jiang WQ, He YJ, Lin TY, Huang HQ, Zhang L, Xia ZJ, Li YH, Zhou ZM, Chen XQ, Xia Y, Zhen ZJ, Guan ZZ.
    Ai Zheng; 2004 Aug 20; 23(8):933-8. PubMed ID: 15301718
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S.
    Cancer; 2004 Jun 15; 100(12):2583-91. PubMed ID: 15197800
    [Abstract] [Full Text] [Related]

  • 16. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M.
    J Clin Oncol; 2004 Jul 01; 22(13):2654-61. PubMed ID: 15159414
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
    Mauro FR, Gentile M, Mancini F, Giannarelli D, Guarini A, De Propriis MS, Cerretti R, Foa R.
    Haematologica; 2002 Jun 01; 87(6):602-8. PubMed ID: 12031916
    [Abstract] [Full Text] [Related]

  • 18. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages.
    De Rossi G, Mauro FR, Caruso R, Monarca B, Mandelli F.
    Haematologica; 1993 Jun 01; 78(3):167-71. PubMed ID: 8375746
    [Abstract] [Full Text] [Related]

  • 19. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA.
    N Engl J Med; 2000 Dec 14; 343(24):1750-7. PubMed ID: 11114313
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.